Helen M. Thackray Insider Trading
Get free email notifications about insider trading for Helen M. Thackray.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Helen M. Thackray. Helen M. Thackray is a Chief R&D Officer in BIOCRYST PHARMACEUTICALS INC ($BCRX) and a Director in BIOCRYST PHARMACEUTICALS INC ($BCRX) and a SVP Clinical Development, CMO in GLYCOMIMETICS INC ($GLYC) and a VP Clinical Development, CMO in GLYCOMIMETICS INC ($GLYC).
Address: C/O GLYCOMIMETICS, INC. 401 PROFESSIONAL DRIVE, SUITE 250 GAITHERSBURG 20879 MD
Companies in which Helen M. Thackray is an Insider
BIOCRYST PHARMACEUTICALS INC
Trading Symbol: BCRXIndustry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Helen M. Thackray: Chief R&D Officer, Director
Holdings: 100,000 shares
Current Value: $567,000
Latest Transaction: Apr 02 2021
$BCRX Market Capitalization: $427.06M
$BCRX Previous Close: $5.67
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
GLYCOMIMETICS INC
Trading Symbol: GLYCIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Helen M. Thackray: SVP Clinical Development, CMO, VP Clinical Development, CMO
Holdings: 183,115 shares
Current Value: $1,146,300
Latest Transaction: Jan 22 2021
$GLYC Market Capitalization: $140.70M
$GLYC Previous Close: $6.26
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Helen M. Thackray
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 02 2021 | BCRX | BIOCRYST PHARMACEU ... | Thackray Helen M. | Chief R&D Officer | Option Exercise | A | 10.17 | 400,000 | 4,068,000 | 400,000 | |
Apr 02 2021 | BCRX | BIOCRYST PHARMACEU ... | Thackray Helen M. | Chief R&D Officer | Grant | A | 0.00 | 100,000 | 0 | 100,000 | 0 to 100 K |
Jan 22 2021 | GLYC | GLYCOMIMETICS INC | Thackray Helen M. | SVP Clinical Develo ... | Option Exercise | A | 3.81 | 69,000 | 262,890 | 69,000 | |
Jan 22 2021 | GLYC | GLYCOMIMETICS INC | Thackray Helen M. | SVP Clinical Develo ... | Grant | A | 0.00 | 34,500 | 0 | 183,115 | 148.6 K to 183.1 K (+23.21 %) |
May 14 2020 | BCRX | BIOCRYST PHARMACEU ... | Thackray Helen M. | Director | Option Exercise | A | 5.41 | 40,000 | 216,400 | 40,000 | |
Jan 24 2020 | GLYC | GLYCOMIMETICS INC | Thackray Helen M. | SVP Clinical Develo ... | Option Exercise | A | 4.72 | 120,000 | 566,400 | 120,000 | |
Sep 24 2019 | BCRX | BIOCRYST PHARMACEU ... | Thackray Helen M. | Director | Option Exercise | A | 2.86 | 40,000 | 114,400 | 40,000 |